Wanbury Limited · NSE:WANBURY
Wanbury — Q2 & H1 FY26 Earnings Presentation
38 slides from Wanbury's earnings presentation, Nov 24, 2025
Slide 1: Regulation 30 disclosure letter to exchanges
November 224, 2025 BSSE Limitedd National Stock S Exchaange of Ind dia Ltd, PJJ. Towers, Exchange Plaza, Banndra Kurla Complex, Daalal Street Bandra (Eaast), Mumbai M – 4000 001. Mumbai – 400 051. Sccript Code: 524212 Script Cod de: WANB BURY Deear Sir/Maadam, ub.: Disclo Su osure undeer Regulattion
Slide 2: Towards Better Healthcare – Earnings Presentation Q2 & H1FY26
Towards Better Healthcare Earnings Presentation Q2 & H1FY26 | November 2025 Wanbury Limited NSE: WANBURY | BSE: 524212 Bloomberg: WANB:IN
Slide 3: Inside this Presentation
Inside this Presentation Company Profile Business Profile Financial Profile Company Profile Business Profile Financial Profile API Business Formulations Business Executive Summary 04 API Business Formulations Business Key Performance Indicators 32 Corporate Journey Strategically Curated 14 Re-Buildi
Slide 4: Company Profile
Executive Summary 04 Corporate Journey 05 Successful Business Turnaround 06 Wanbury at a Glance 07 Company Business Streams 08 Board of Directors 09 Senior Leadership 10 R&D Capabilities 11 Profile Environment, Health & Safety 12
Slide 5: Executive Summary
0 1 / C OM PA N Y P ROF IL E Executive Summary Successful Global market Building new De-risked & turnaround to leaderships in growth drivers in robust balance growth momentum key products API business sheet Operational & financial Globally significant Through launch of an Refinanced debt & healthy t
Slide 6: Corporate Journey
0 1 / C OM PA N Y P ROF IL E Corporate Journey 1990-2000 2000-2010 2010-2023 2024-Onwards 1990-2000 2000-2010 2010-2023 2024-Onwards Foundation Early Strategic Acquisitions Corporateinto Venture Consolidation Developed Markets Challenges Business Turnaround Transformation Growth Foundation & Early S
Slide 7: Successful Business Turnaround
0 1 / C OM PA N Y P ROF IL E Successful Business Turnaround Financial Turnaround Operational Turnaround Debt reduction: ~75% reduction from peak- Capacity ramp-up in key existing API debt obligation of ~700 Crores, including products through de-bottlenecking: corporate guarantee from Wanbury Limited
Slide 8: Wanbury at a Glance
0 1 / C OM PA N Y P ROF IL E Wanbury at a Glance 6 products, 10+ brands, 2 USFDA 100% chronic acute & approved API portfolio semi-chronic facilities Formulations Portfolio with 386 KL cumulative API Portfolio reactor capacity 80%+ 1,200+ 37+ years Export top line, with Employee strength Operating hi
Slide 9: Business Streams
0 1 / C OM PA N Y P ROF IL E Business Streams API Formulations API manufacturer building a niche, Rebuilding legacy brand formulations profitable & sustainable business business in India (50%+ Gross contribution margins) 12% 10+ active brands + additional Diversified business stream across launches
Slide 10: Board of Directors
0 1 / C OM PA N Y P ROF IL E Board of Directors Mr. Mohan Kumar Mr. K. Dr. Anupama Mr. Mridul Mr. Manoj Mr. Pallavur Rayana Chandran Vaidya Mehta Gursahani Sankar Das Promoter & Whole Time Whole Time Director Non Executive Non Executive Non Executive Non Executive Director Independent Woman Independ
Slide 11: Senior Leadership
0 1 / C OM PA N Y P ROF IL E Senior Leadership Mr. Vinod Verma Mr. Prakash Venkatraman Mr. Rashesh Patel Chief Financial Officer President – API Business President – India Formulations Business 30+ years of experience 30+ years of experience 35+ years of experience Mr. Vinod Verma is a qualified Cha
Slide 12: R&D Capabilities
0 1 / C OM PA N Y P ROF IL E R&D Capabilities R&D Capabilities API R&D Center Formulations R&D Center Process Optimization: Optimization of synthesis routes for enhanced yields & lowering costs Impurity Control: Advanced analytical techniques aligned with ICH guidelines Analytical Excellence: Locati
Slide 13: Environment, Health & Safety
0 1 / C OM PA N Y P ROF IL E Environment, Health & Safety EHS at Wanbury • Best-in-class standards: Committed to • Safety culture: Comprehensive global EHS norms and strict regulatory training, systematic risk compliance across all operations assessments (HAZOP), and robust • Environmental focus: Ze
Slide 14: Business Profile: API
Strategically Curated 14 Product Portfolio Business World-Class Manufacturing 15 Infrastructure CAPEX Tracker 16 Profile: Developed Market 17 Focused Business Profile Regulatory Approvals 18 Manufacturing Capabilities API 19 Strategy & Way Forward 20 Safety First Culture 21
Slide 15: API: Strategically Curated Product Portfolio
0 2 / B U S I N ES S P R O F I L E: A P I API: Strategically Curated Product Portfolio Significant global market share in Top 3 products Molecule Therapeutic Category Global Market (MT) Estimated Market Share Metformin Antidiabetic ~75,000 ~11% Sertraline Antidepressant ~680 ~30% Tramadol Pain Manag
Slide 16: API: World-Class Manufacturing Infrastructure
0 2 / B U S I N ES S P R O F I L E: A P I API: World-Class Manufacturing Infrastructure Cumulative installed Site 1: Tanuku, Andhra Pradesh Site 2: Patalganga, Maharashtra reactor capacity: 500 KL Future reactor capacity potential at existing sites: 600 KL 400 KL Multi-Purpose Plant 96 KL Dedicated
Slide 17: API: CAPEX Tracker
0 2 / B U S I N ES S P R O F I L E: A P I API: CAPEX Tracker 4 FY27 (P) 3 Total – ₹63 Cr • New Clean Room Facility – FY26 (P) ₹12 Cr 2 Total – ₹64 Cr • New Production Block + 2 Clean Rooms – ₹45 Cr • Replacements – ₹12 Cr FY25 (A) • New Storage Area – ₹6 Cr 1 Total – ₹48 Cr • Debottlenecking – ₹14 C
Slide 18: API: Developed Market Focused Business Profile
0 2 / B U S I N ES S P R O F I L E: A P I API: Developed Market Focused Business Profile Focused on regulated markets Exporting to 50+ countries Exporting to 4+ continents Total Revenue Mix 20% 80% Exports Domestic Map not to scale, only for illustration purpose. Investor Presentation | Wanbury Limi
Slide 19: API: Regulatory Approvals
0 2 / B U S I N ES S P R O F I L E: A P I API: Regulatory Approvals US-FDA US – FDA Europe – EDQM Brazil – ANVISA South Korea – KFDA Mexico – COFEPRIS WHO GMP WHO GMP Approval since 2000 Approval since 2007 Approval since 2024 Approval since 2012 Approval since 2013 Approval since 2007 Approval sinc
Slide 20: API: Manufacturing Capabilities
0 2 / B U S I N ES S P R O F I L E: A P I API: Manufacturing Capabilities Chemistry Reaction System Capabilities Capabilities Capabilities • Azidation • High Pressure Reactions • Deployed SAP S4 HANA • Bromination • High Vacuum Distillations • Dedicated software for Sales & • Cyanation • Direct Comp
Slide 21: API: Strategy & Way Forward
0 2 / B U S I N ES S P R O F I L E: A P I API: Strategy & Way Forward Product Selection Framework Way Forward Mid-Size Molecules Targeted expansion in regulated markets (US, EU, Brazil) – new & existing molecules Small-to-Mid size molecules + Aim double- digit market share 4 commercial launches of n
Slide 22: API: Safety First Culture
0 3 / B U S I N ES S P R O F I L E: F O R M U L A T I O N S API: Safety First Culture Investor Presentation | Wanbury Limited 21
Slide 23: Business Profile: Formulations
Re-Building Business 23 Business Brand Portfolio 24 Strategy & Way Forward 25 Profile: Formulations
Slide 24: Formulations: Re-Building Business
0 3 / B U S I N ES S P R O F I L E: F O R M U L A T I O N S Formulations: Re-Building Business Formulations - Revenue & Share Overview • Formulations business journey 13% commenced in 1995 with the 11% 12% 10% acquisition of Wander Ltd, formerly a 9% division of Sandoz • Current portfolio is focused
Slide 25: Formulations: Brand Portfolio
0 3 / B U S I N ES S P R O F I L E: F O R M U L A T I O N S Formulations: Brand Portfolio Top brands Anti Cold & Cough Pain & Inflammation, Antacids & Anti-ulcerants Herbal Laxative Muscular Spasm Protein Supplement Calcium Supplement - Nutritional Supplement Multivitamin Supplement Osteoporosis & B
Slide 26: Formulations: Strategy & Way Forward
0 3 / B U S I N ES S P R O F I L E: F O R M U L A T I O N S Formulations: Strategy & Way Forward Operational Objectives Strategic Way Forward Leverage 3+ decades of heritage to re-build a 1 Latest brand launch (FY25) scalable branded formulations franchise C RED (Iron Supplement) Transition portfoli
Slide 27: Q2 & H1FY26 Earnings Update
Performance Highlights 27 Business Vertical Performance Q2 & H1FY26 28 P&L Snapshot 29 Management Commentary 30 Earnings Update
Slide 28: Q2 & H1FY26 Performance Highlights
0 4 / Q 2 & H 1F Y 2 6 EA R NI N G S U P D AT E Q2 & H1FY26 Performance Highlights Revenue (in ₹ Crore) 161 163 323 160 292 -0.7% 10.6% QOQ GROWTH YOY GROWTH Q2FY25 Q1FY26 Q2FY26 H1FY25 H1FY26 EBITDA (in %) 25 26 51 22 34 20% 51% QQQ GROWTH YOY GROWTH Q2FY25 Q1FY26 Q2FY26 H1FY25 H1FY26 PAT (in ₹ Cro
Slide 29: Business Vertical Performance
0 4 / Q 2 & H 1F Y 2 6 EA R NI N G S U P D AT E Business Vertical Performance API - Revenue (in ₹ Crore) 142 277 141 135 256 -5.0% 8.2% QOQ GROWTH YOY GROWTH Q2FY25 Q1FY26 Q2FY26 H1FY25 H1FY26 Formulations - Revenue (in ₹ Crore) 22 19 40 18 34 22.2% 17.6% QOQ GROWTH YOY GROWTH Q2FY25 Q1FY26 Q2FY26 H
Slide 30: Q2 & H1 P&L Snapshot
0 4 / Q 2 & H 1F Y 2 6 EA R NI N G S U P D AT E Q2 & H1FY25 P&L Snapshot PARTICULARS (in ₹ Crore) Q2FY25 Q1FY26 Q2FY26 YOY Change QOQ Change H1FY25 H1FY26 YOY Change Revenue from Operations 161.19 163.18 160.06 -1% -2% 292.3 323.2 10.57% Other Income 1.63 0.35 0.20 -88% -42.86% 2.58 0.55 -78.68% COG
Slide 31: Management Commentary
0 1 / Q 2 & H 1F Y 2 6 EA R NI N G S U P D AT E Management Commentary Q2 continues to be stronger with EBITDA achievement of ₹ 26.0 (16.2%) crore as compared to ₹21.6 (13.3%) crore in Q2 FY25, registering a growth of 20% over previous quarter, overall improvement of 292 bps of revenues. Further, ach
Slide 32: Financial Profile
Key Performance Indicators 32 5Y P&L Snapshot 33 5Y Balance Sheet Snapshot 34 5Y Cash Flow Snapshot 35 Financial Capital Markets Overview 36 Profile
Slide 33: Key Performance Indicators
05 1 / FQI 2NA&NH C1F I AYL 2P6REA O FRI LNIE N G S U P D AT E Key Performance Indicators Revenue from Gross Profit & EBITDA & PAT & Operations (in ₹ Crore) Gross Margins (in ₹ Crore & in %) EBITDA Margins (in ₹ Crore & in %) PAT Margins (in ₹ Crore & in %) 70 0. 0 Gross Profit Gross Margin EBITDA E
Slide 34: 5Y P&L Snapshot
0 5 / F I NA N C I A L P R O F I L E 5Y P&L Snapshot PARTICULARS (in ₹ Crore) FY21 FY22 FY23 FY24 FY25 H1 FY26 Revenue from Operations 392.5 511.2 499.7 575.7 599.51 323.2 Other Income 2.4 1.51 0.91 2.99 3.49 0.55 COGS 221.3 300.3 303.4 302.6 294.47 142.4 Gross Profit 173.6 212.4 197.1 276 308.53 18
Slide 35: 5Y Balance Sheet Snapshot
0 5 / F I NA N C I A L P R O F I L E 5Y Balance Sheet Snapshot PARTICULARS (in ₹ Crore) FY21 FY22 FY23 FY24 FY25 H1 FY26 Equity Share Capital Equity Share Capital 25.01 32.67 32.7 32.74 32.77 34.88 Other Equity -155.7 -30.48 -39.96 -4.8 26.5 72.35 Non-Current Liabilities Long Term Borrowings 71.99 -
Slide 36: 5Y Cash Flow Snapshot
0 5 / F I NA N C I A L P R O F I L E 5Y Cash Flow Snapshot PARTICULARS (in ₹ Crore) FY21 FY22 FY23 FY24 FY25 H1 FY26 Cash Flow from Operating Activities 16.68 37.56 19.8 4.02 26.1 -5.66 Cash Flow from Investing Activities 8.04 0.59 -8.84 -16.62 -51.17 -15.27 Cash Flow from Financing Activities -17.3
Slide 37: Capital Markets Overview
0 5 / F I NA N C I A L P R O F I L E Capital Markets Overview Shareholding Pattern (%) 0.81 Current Market Price ₹230 56.10 43.09 52 Week High/Low ₹330 / ₹154 Market Capitalization ₹800 Crore No. of Shares Outstanding 3.49 Crore NSE WANBURY Promoters Public FIIs + DIIs BSE 524212 Shareholding data a
Slide 38: Wanbury – Towards Better Healthcare
WANBURY Towards Better Healthcare Wanbury Limited Chief Financial Officer Company Secretory investor@wanbury.com / ges@wanbury.com investorelations@wanbury.com til TIL Advisors Private Limited Adfactors PR Investor Relations Advisor Investor Relations Advisor soyometneinvestmentiab.in Honishi.shonSa